Sirius XM Rallies on Deutsche Bank Upgrade and Digital Audio Upside
Shares moved on overlooked YouTube U.S. audio ads and stronger 2026 results.
Already have an account? Sign in.
Shares moved on overlooked YouTube U.S. audio ads and stronger 2026 results.
The FDA approved Scholar Rock’s Isembyld, the first SMA therapy aimed at muscle wasting in patients already on nerve-targeted treatment.
The Phase III SERENA-4 trial did not meet its primary PFS endpoint in untreated advanced ER-positive, HER2-negative breast cancer, despite a numerical benefit.
Citi added a 90-day upside view on AppLovin with a $600 target, calling Q3 concerns misguided.